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Abstract: Amoxicillin-clavulanic acid (AMC) belongs to the WHO Essential Medicines List for
children, but for optimal antimicrobial effectiveness, reconstituted dry powder suspensions need
to be stored in a refrigerated environment. Many patients in low- and middle-income countries
who are sold AMC suspensions would be expected not to keep to the specified storage conditions.
We aimed to assess the stability of both ingredients in liquid formulations and dispersible tablets,
combined with nationally representative data on access to appropriate storage. Degradation of
amoxicillin (AMX) and clavulanic-acid (CLA) was measured in suspensions and dispersible tablets
commercially available in Switzerland at different ambient temperatures (8 ◦C vs. 28 ◦C over 7 days,
and 23 ◦C vs. 28 ◦C over 24 h, respectively). Data on access to refrigeration and electricity were
assessed from the USAID-funded Demographic and Health Survey program. In suspensions, CLA
degraded to a maximum of 12.9% (95% CI −55.7%, +29.9%) at 8◦C and 72.3% (95% CI −82.8%,
−61.8%) at a 28 ◦C ambient temperature during an observation period of 7 days. Dispersible tablets
were observed during 24 h and CLA degraded to 15.4% (95% CI −51.9%, +21.2%) at 23 ◦C and
21.7% (−28.2%, −15.1%) at a 28 ◦C ambient temperature. There is relevant degradation of CLA in
suspensions during a 7-day course. To overcome the stability challenges for all active components,
durable child-appropriate formulations are needed. Until then, prescribers of AMC suspensions
or pharmacists who sell the drug need to create awareness for the importance of proper storage
conditions regarding effectiveness of both antibiotics and this recommendation should be reflected in
the WHO Essential Medicines List for children.
Keywords: amoxicillin-clavulanic acid; clavulanate; degradation; child-appropriate formulation
1. Introduction
Understanding and tracking patterns of antibiotic consumption over time and across
countries is essential to ensure appropriate access. Young children are of particular interest,
as they have a disproportionately high use of antibiotics [1].
A recent study analyzed 2011–2015 trends in the consumption of child-appropriate
formulations (CAFs, defined as oral liquid formulations and solid formulations that are
primarily dissolved or dispersed or become liquid upon swallowing) for under-fives in
36 low- and middle-income countries (LMICs) and 39 high-income countries (HICs) [1].
Antibiotic sales increasing by 8.6% per year mainly driven by LMICs were observed, with
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amoxicillin (AMX) with and without clavulanic-acid (AMC) being among the antibiotics
with the highest sales volume globally [1]. Both AMX and AMC are listed as Access
antibiotics on the 2019 revision of the WHO Essential Medicines List for children, this
group representing the core set of antibiotics, which should be consistently available at an
appropriate quality, formulation and price [2,3].
CAFs of many antibiotics are limited to dry powder suspensions, some of which have
to be stored refrigerated once reconstituted, including AMC, due to stability limitations of
the active ingredients (a drug substance is said to be stable when no more than 10% of its
original content is degraded during the storage period [4]). However, many consumers
cannot keep to the specified storage conditions for different reasons, such as lack of access
to a refrigerator or irregular power supply. This raises concerns about the inappropriate
use of such formulations, especially in LMICs. Given the high rate of use of oral AMC
reported in LMICs, it is necessary to explore the stability of either active substance as it
would be stored in real life (i.e., in suspension).
We aimed to assess the stability of both AMX and CLA in co-formulated and non-
co-formulated commercially available liquid formulations and dispersible tablets under
different storage conditions, combined with nationally representative data on access to
appropriate storage conditions in a range of LMICs.
2. Results
2.1. Stability Data
2.1.1. Amoxicillin-Clavulanic Acid: Co-Formulated Suspensions
For AMC co-formulated suspensions, AMX was largely stable after 7 days at 8 ◦C with
a degradation of 1.4% (95% CI −31.0%, +28.3%, p = 0.026) (mean of all 4 tested products,
Figure 1a). With a higher ambient temperature of 28 ◦C, AMX degradation increased to
15.3% (95% CI −47.5%, +16.9%, p < 0.01) after 7 days (Figure 1b, Table S1 in Supplementary
Materials).
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Figure 1. Degradation of Amoxicillin (a,b) and Clavulanic acid (c,d) in co-formulated suspensions at 8 °C (a,c) versus 28 
°C (b,d). Degradation is normalized for the median value at time point 0 (0% degradation). Data points represent the 
normalized individual measurements for Augmentin Duo (square), Augmentin Trio (circle), Aziclav Duo (triangle) and 
Aziclav Forte (diamond). Cross bar represents the mean and the whiskers indicate the 95% confidence interval (mean ± 2 
SD) per time point. 
In summary, there is adequate stability of AMX in co-formulated suspensions under 
both temperature conditions, but markedly and statistically significant decreased CLA 
levels from day 4 onwards at an ambient temperature of 28 °C. 
2.1.2. Amoxicillin-Clavulanic Acid: Co-Formulated Dispersible Tablets 
Testing dispersed AMC co-formulated dispersible tablets over a period of maximally 
24 h, AMX showed a degradation of 14.4% (95% CI −25.5%, −3.2%, p < 0.01) at 23 °C and 
15.5% (95% CI −21.1%, −9.9%, p < 0.01) at 28 °C (Figure 2a,b, Table S3 in Supplementary 
Materials). 
For the same formulation, CLA degradation showed similar results at 23 °C (mean 
15.4%; 95% CI −51.9%, +21.2%, p < 0.01) (Figure 2c), but degradation increased to 21.7% 
(−28.2%, −15.1%, p < 0.01) with a 28 °C ambient temperature (Figure 2d, Table S4 in Sup-
plementary Materials). 
Figure 1. Degradation of Amoxicillin (a,b) and Clavulanic acid (c,d) in co-formulated suspensions at 8 ◦C (a,c) versus
28 ◦C (b,d). Degradation is normalized for the median value at time point 0 (0% degradation). Data points represent the
normalized individual measurements for Augmentin Duo (square), Augmentin Trio (circle), Aziclav Duo (triangle) and
Aziclav Forte (diamond). Cross bar represents the mean and the whiskers indicate the 95% confidence interval (mean
± 2 SD) per time point.
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The stability data of CLA in co-formulated suspensions at 8 ◦C and 28 ◦C is shown in
Figure 1c,d and Table S2 in Supplementary Materials. CLA degradation was 12.9% (95% CI
−55.7%, +29.9%, p < 0.01) at 8 ◦C and increased to 72.3% (95% CI −82.8%, −61.8%, p < 0.01)
with a 28 ◦C ambient temperature.
In summary, there is adequate stability of AMX in co-formulated suspensions under
both temperature conditions, but markedly and statistically significant decreased CLA
levels from day 4 onwards at an ambient temperature of 28 ◦C.
2.1.2. Amoxicillin-Clavulanic Acid: Co-Formulated Dispersible Tablets
Testing dispersed AMC co-formulated dispersible tablets over a period of maximally
24 h, AMX showed a degradation of 14.4% (95% CI −25.5%, −3.2%, p < 0.01) at 23 ◦C and
15.5% (95% CI −21.1%, −9.9%, p < 0.01) at 28 ◦C (Figure 2a,b, Table S3 in Supplementary
Materials).
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and Sandoz 1000 mg (diamond) tablets. Cross bar represents the mean and the whiskers indicate the 95% confidence 
interval (mean ± 2 SD) per time point. 
Overall, some statistically significant degradation was demonstrated for all compo-
nents, but this is more marked for CLA at 28 °C. 
2.1.3. Amoxicillin: Suspensions and Dispersible Tablets 
For non-co-formulated AMX, levels remained stable during a 7-day period at 8 °C (p 
= 0.671) or 28 °C temperature for suspensions with a slightly increased degradation at the 
higher temperature (9.0%; 95% CI −23.4%, +5.4%, p < 0.01), Figure 3a,b, Table S5 in Sup-
plementary Materials). 
For dispersible AMX tablets, the amount of AMX remained relatively stable after 24 
h at 23 °C and 28 °C (p = 0.176 and p = 0.007, respectively, Figure 3c,d, Table S6 in Supple-
mentary Materials). 
Figure 2. Degradation of Amoxicillin (a,b) and Clavulanic acid (c,d) at 23 ◦C (a,c) versus 28 ◦C (b,d) in co-formulated tablets
(dissolved). Degradation is normalized for the median value at time point 0 (0% degradation). Data points represent the
normalized individual measurements for Mepha 625 mg (square), Mepha 1000 mg (circle), Sandoz 625 mg (triangle) and
Sandoz 1000 mg (diamond) tablets. Cross bar represents the mean and the whiskers indicate the 95% confidence interval
(mean ± 2 SD) per time point.
For the same formulation, CLA degradation showed similar results at 23 ◦C (mean
15.4%; 95% CI −51.9%, +21.2%, p < 0.01) (Figure 2c), but degradation increased to 21.7%
(−28.2%, −15.1%, p < 0.01) with a 28 ◦C ambient temperature (Figure 2d, Table S4 in
Supplementary Materials).
Overall, some statistically significant degradation was demonstrated for all compo-
nents, but this is more marked for CLA at 28 ◦C.
2.1.3. Amoxicillin: Suspensions and Dispersible Tablets
For non-co-formulated AMX, levels remained stable during a 7-day period at 8 ◦C
(p = 0.671) or 28 ◦C temperature for suspensions with a slightly increased degradation at
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the higher temperature (9.0%; 95% CI −23.4%, +5.4%, p < 0.01), Figure 3a,b, Table S5 in
Supplementary Materials).
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pensions and dispersible tablets, respectively, even though the former products were 
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The number of households with access to electricity ranged from 8.7% in Burundi to 
99.8% on the Maldives (mean across 33 countries 44.8%). A minimum of 1.4% of house-
holds in Burundi had a refrigerator in the latest survey period, while almost all house-
holds (97.8%) had access to refrigeration on the Maldives (mean all countries: 18.5%) [5] 
(Figure 4a,b, Table S7 in Supplementary Materials). Of note, while ≥75% of households 
reported access to electricity in Ghana, India, the Maldives, Nepal, Pakistan, the Philip-
pines and South Africa, access to refrigeration was ≥75% only in the Maldives. For 14 
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Figure 3. Degradation of Amoxicillin in non-co-formulated suspensions (a,b) at 8 ◦C (a) versus 28 ◦ (b) or tablets (dissolved;
c, d) at 23 ◦C (c) versus 28 ◦C (d). Degradation is normalized for the median value at time point 0 (0% degradation). Data
points represent the normalized individual measurements for Mepha (square) and Sandoz (triangle) suspensions and
Sandoz 1000 mg tablets (diamonds). Cross bar represents the mean and the whiskers indicate the 95% confidence interval
(mean ± 2 SD) per time point.
For dispersible AMX tablets, the amount of AMX remained relatively stable after
24 h at 23 ◦C and 28 ◦C (p = 0.176 and p = 0.007, respectively, Figure 3c,d, Table S6 in
Supplementary Materials).
Altogether, AMX was largely stable over 7 days and 24 h in non-co-formulated
suspensions and dispersible tablets, respectively, even though the former products were
slightly less stable at higher temperatures than the latter.
2.2. DHS Data on Access to Electricity and Refrigeration
The number of households with access to electricity ranged from 8.7% in Burundi to
99.8% on the Maldives (mean across 33 countries 44.8%). A minimum of 1.4% of households
in Burundi had a refrigerator in the latest survey period, while almost all households (97.8%)
had access to refrigeration on the Maldives (mean all countries: 18.5%) [5] (Figure 4a,b,
Table S7 in Supplementary Materials). Of note, while ≥75% of households reported access
to electricity in Ghana, India, the Maldives, Nepal, Pakistan, the Philippines and South
Africa, access to refrigeration was ≥75% only in the Maldives. For 14 countries, average
bulb temperature was additionally available and ranged from 15 to 28 ◦C Table S7 in
Supplementary Materials) [5].
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3. Discussion
This study comprehensively describes the egradation of AMX and CLA as i gredi-
ents of co-formulated and non-co-formulated child-appropriate formulations. Our main
finding is that CLA in co-formulated suspensions degrades considerably at storage tem-
peratures representative of ambient temperatures in many parts of the world where this
antibiotic and formulation is commonly used. While consumption of CAFs of AMX and
AMC in HICs have remained largely unchanged, CAF sales increased in LMICs by 6.8%
per year [1]. Although the combination is recommended as first-choice treatment only for
specific indications [2], LMIC use of AMC almost equaled that of AMX in 2015 [1].
The recommended storage temperature for AMX sodium solution is 2–8 ◦C. It is
stable at higher temperatures for only short periods of time, e.g., 8 or 3 h at 25 ◦C in
sodium chloride or water for injection, respectively [6,7]. There is little data (with robust
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reporting allowing for reproducibility) on stability at higher temperatures. Stability of
at least 90% of AMX at 25 ◦C and even 40 ◦C in prepared unit dose syringes for 78 and
10 days, respectively, has been reported for injectable formulations [8]. Recent studies
could not confirm these results and demonstrated more rapid degradation under similar
conditions. For oral formulations, Mehta et al. describe 90% conservation of reconstituted
AMX at 20 ◦C for only 7 days [9], while Peace et al. observe only 79% conservation at
7 days at a temperature of 27–29 ◦C [10].
Importantly, CLA is not as heat stable as AMX in either intravenous or reconstituted
oral suspension form. Its stability in aqueous solutions has been poorly characterized,
though one study reported that after 7 h at 35 ◦C, about 50% clavulanic acid degraded and
90% after 24 h [11]. Reconstituted oral suspensions appear to be somewhat more stable if
storage conditions are appropriate. At 2–8 ◦C, Mehta et al. observe only 10% degradation
after 7 days, while at 20 ◦C or 27–29 ◦C ambient temperature, degradation rises to 40% or
45%, respectively [9,10]. Various degradation will likely be the case when oral suspensions
are used for administration to young children in settings without secure reliable access to
refrigeration. Therefore, it is necessary to explore the stability of either active substance, as
it would be stored in real life (i.e., in suspension). Stability testing in this context should
reflect how the quality of the active substance varies with time, influenced by a variety
of environmental factors such as temperature, humidity and light [10]. In this context,
it is important to consider that the content uniformity of a drug may vary according
to manufacturer information (i.e., the amount of drug as indicated ±25% according to
pharmaceutical industry standards [12]).
In our study, the simulation of inappropriate storage conditions with ambient temper-
atures of max. 28 ◦C led to a relevant degradation of CLA in co-formulated suspensions
of 72% on average after 7 days, which resembles a regular period of “treatment time” for
infections such as community-acquired moderate-severe pneumonia when the reconsti-
tuted medication is kept at home [13]. The same but less marked effect was seen for CLA
in co-formulated dispersible tablets, if they were dissolved and left for up to 24 h before
administering it. However, this scenario is less likely, compared with suspensions being
reconstituted once and then stored for the whole treatment period. The most important
message for dispersible tablets is that extensive mixing is required before usage in order
not to have a precipitate, which then is not ingested.
Our results corroborate earlier studies showing that at 8 ◦C CLA maintains at least 90%
of its initial concentration for 7 days, though at 20 ◦C only 60% is maintained in the same
time period [9] and at 27–29 ◦C, only 55% [10]. Another study recently showed similar
results, with CLA being the stability-limiting factor from day 2 onwards [14]. Additionally,
we found that AMX showed somewhat poorer stability in co-formulated products when
the product is not stored refrigerated as recommended. Liquid formulations generally
tend to have much shorter shelf lives than solid formulations, amongst other reasons
because adjuncts such as sweeteners, flavoring as well as suspending, stabilizing and
preserving agents are added. These ingredients make the formulations very prone to
physical, chemical and microbiological instability [10].
Testing of dispersible tablets shows that both components—AMX and CLA—are
satisfactorily stable, even at high ambient temperatures. Unfortunately, these tablets
are less flexible in terms of weight-based dosing and the application of technologies
used for orally dissolving tablet (ODTs) is limited by the amount of drug that can be
incorporated into each unit dose [15]. Therefore, with increasing doses, tablets need
to be dissolved in water or any other clean liquid (e.g., breast-milk), which might not
be available all the time all over the world. Additionally, dividing a dispersed tablet
in several equal portions seems to be impractical due to fast precipitation. However,
organizations like UNICEF increasingly supply AMX tablets in a dispersible form as
a child-friendly pediatric dosage [16], as they provide various advantages compared
with suspensions, including blister packaging simplifying dispensing and supply, tablets
offering an accurately measured dose of antibiotic, having a comparatively lower volume
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and weight, generating less waste and offering greater logistical and supply chain efficiency
through to end-users in a community without any cold chain requirements.
In the context of our observations, oral AMC suspensions currently in use are problem-
atic for two main reasons. First, the co-formulated suspension normally is more expensive
than AMX alone and is widely sold to a population where a relevant part of households
cannot keep to the specified storage conditions. In some of the evaluated countries, the
costs for the co-formulated product compared with AMX alone were up to 3 times more ex-
pensive: e.g., UNICEF medical supply division: AMX 125 mg per 5 mL, 100 mL suspension:
0.45 USD indicative price versus AMC 125/31.25 mg per 5 mL, 100 mL suspension: 1.41
USD indicative price [17]. For South Africa: AMX 250 mg per 5 mL, 100 mL suspension:
R8.27–9.99 versus AMC 250/62.5 mg per 5 mL, 100 mL suspension: R28.92 [18], which is
about the same ratio as for Switzerland [19].
Wealth indices are a helpful tool to set the costs per antibiotic course in relation to
the income of families in LMICs, when reliable data on income and expenditures are
unavailable. Evaluating variables such as access to electricity and refrigeration from the
DHS program showed that overall less than 20% of households from the selected countries
from the Sub-Saharan and South/Southeast Asian continent possessed a refrigerator and
therefore access to proper storage conditions for oral formulations of AMC in 2014–2018. A
study from Durban/South Africa (which is listed as an upper-middle income country by the
World Bank list of economies, June 2020 [20] and where 75% of households possess a fridge)
reports that almost half of the patients stored their antibiotic (AMX) suspensions outside
the fridge in common areas of the house like e.g., the kitchen, bedroom or bathroom [21].
Second, there are insufficient data supporting a better efficacy of AMC compared with
AMX alone for key indications like community-acquired pneumonia (CAP) in under-fives.
Most guidelines (e.g., British Thoracic Society, European Society for Paediatric Infectious
Diseases, Infectious Diseases Society of America) recommend oral AMX as first line for
CAP and AMC for suspected staphylococcal infection, e.g., in pneumonia associated
with influenza [22–26]. There are clear potential benefits of prescribing the combination
instead of AMX alone: the patient receives a broader spectrum antibiotic and is covered
for a wider range of pathogens. This approach has many advantages, especially in LMIC
where access to healthcare is difficult and the patient has no easy possibility to return
in case of non-improvement. However, overuse of broader spectrum agents is the main
accelerator of emergence of resistance, including resistance to “downstream” antibiotics
such as cephalosporins, fluoroquinolones and carbapenems.
Hence, there is urgent need to generate robust trial data to support the use of AMC in
specific indications together with a requirement to develop better formulations to overcome
the stability challenges for all active components (e.g., dispersible tablets or ODTs), if AMC
indeed is more efficacious for the treatment of specific infections. Until these goals are
reached, the prescribers of AMC suspensions or pharmacists who sell the drug need to
create awareness for the importance of proper storage conditions regarding effectiveness
of both antibiotics. If these conditions cannot be reached, i.e., effectiveness of the drug
cannot be guaranteed, changing the formulation of AMC (to e.g., solid or dispersible
tablets) or changing the drug (to e.g., a second-line therapy) should be considered. This
recommendation should be reflected in the WHO Essential Medicines List for children.
4. Materials and Methods
4.1. Degradation Kinetics of Clavulanic Acid and Amoxicillin
Degradation over time of AMX and AMC suspensions commercially available in
Switzerland was tested at different temperatures. Each product was tested in triplicate,
three samples were taken from each bottle at every sampling point (i.e., n = 3 samples
per product and sampling point) and the average degradation was determined during a
storage period of 7 days as roughly corresponding to an antibiotic course prescribed in the
community. The bottles were stored at 8 ◦C, corresponding to refrigeration, and at 28 ◦C,
simulating average ambient temperature in many LMICs.
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Additionally, stability of commercially available dispersible tablets of AMX and AMC
once dispersed according to the manufacturer’s instructions was tested during 24 h at
standard room temperature (23 ◦C) and at 28 ◦C.
Storage at room temperature was in natural light on the bench in a room with air-
conditioning, which kept the temperature at approximately 23 ◦C all day. The samples
stored in the refrigerator were kept in the dark in a temperature-controlled fridge at 8 ◦C.
Storage at elevated temperature was in the dark in a humidity and temperature-controlled
incubator at 28 ◦C. The tested products are listed in Table 1.




Aziclav Duo (400 mg, 57 mg/mL)
Aziclav Forte (250 mg, 62.5 mg/5mL)
GlaxoSmithKline
(Brentford, United Kingdom)
Augmentin Duo (400 mg, 57 mg/5mL)




Co-Amoxi-Mepha Dispersible 1000 mg (875 mg/125 mg)
Co-Amoxi-Mepha Dispersible 625 mg (500 mg/125 mg)
Sandoz Pharmaceuticals
(Rotkreuz, Switzerland)
Amoxicillin Sandoz (200 mg Amoxicillin/4 mL)
Amoxicillin Sandoz 1000 (1000 mg Amoxicillin per tablet)
Co-Amoxicillin Sandoz 625 (500 mg/125 mg per tablet)
Co-Amoxicillin Sandoz 1 g (875 mg/125 mg per tablet)
All products were prepared according to the manufacturers’ instructions. Suspension
bottles were filled to the marked line using tap water and shaken vigorously at reconstitu-
tion and before each sample was taken. Dispersible tablets were dissolved in 100 mL tap
water and mixed using a magnetic stirrer during sample withdrawal. Constant mixing
of the samples during withdrawal was necessary to achieve uniform sampling, since the
dispersions separated quickly.
Liquid formulations (suspensions) were diluted 1:1000 with water and dispersions
were diluted 1:100. Solvation was assisted by ultrasonic application. To each 100 µL of
sample solution 900 µL internal standard solution (1 mg/l AMX-d4 in methanol) were
added before measurement. The samples were analyzed using an UltiMate 3000 HPLC
system (Thermo Scientific, Reinach, Switzerland) coupled to a triple quadrupole mass
spectrometer (TSQ ENDURA, Thermo Scientific, Reinach, Switzerland) applying electro-
spray ionization as published before [27]. Chromatographic separation was performed
on an Accucore™ XL C18 4 µm 150 × 4.6 mm column (Thermo Fisher Scientific, Reinach,
Switzerland) with a binary gradient of 10 mM ammonium acetate in water, adjusted to
pH 8 with acetic acid (mobile phase A) and 10 mM ammonium acetate and 0.1% formic
acid in methanol/acetonitrile (1/1, v/v) (mobile phase B). Samples were quantified against
calibrators containing AMX and CLA in water.
4.2. Data Analysis and Visualization
As for each product, triplicate measurements of three samples were taken, n = 9
samples were included per product. For the co-formulated suspensions and tablets, four
products were analyzed, leading to a total of n = 36 samples available for statistical analysis.
Two non-co-formulated suspensions and one non-co-formulated tablet were included in
the analysis, which resulted in a total of n = 18 and n = 9 samples available for statistical
analysis, respectively. A paired t-test was used to compare the means of degradation across
all formulations (n = 36, n = 18, or n = 9 as described above) at different time points with
the mean of the first measurements, with a calculated p-value < 0.01 considered to be
statistically significantly different.
Additionally, for each time point, descriptive statistics were applied and the mean,
median, standard deviation (SD), standard error and 95% confidence interval (95% CI,
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mean ± 2SD) of triplicates of all three samples from bottles or tablet dispersions were
calculated. Data was normalized by the median per product, with 0% degradation at the
start of the study. Data visualization of the individual and mean ± 2 SD measurements per
time point was performed using R (version 3.5.1) and RStudio (version 1.1.456).
4.3. DHS Data on Access to Electricity and Refrigeration
To assess the likely frequency of a lack of cold storage in the home, the STAT-
compiler from the USAID-funded Demographic and Health Survey (DHS) program
(www.statcompiler.com, accessed on 27 October 2020) was used to assess datasets for ac-
cess to refrigeration and electricity for 33 countries from Sub-Saharan Africa and South/
Southeast Asia [5]. Surveys were run within the last five years with available data from
2014–2018. Map visualizations were created using the ggmap and maps packages in R.
Supplementary Materials: The following are available online at https://www.mdpi.com/2079
-6382/10/2/225/s1, Table S1: Degradation of Amoxicillin in the Amoxicillin-clavulanic acid co-
formulated suspensions at 28 ◦C and 8 ◦C; Table S2: Degradation of Clavulanic acid in Amoxicillin-
clavulanic acid co-formulated suspensions at 28 ◦C and 8 ◦C; Table S3: Degradation of Amoxicillin in
dispersed Amoxicillin-clavulanic acid co-formulated dispersible tablets at 28 ◦C and 23 ◦C; Table S4:
Degradation of Clavulanic acid in dispersed Amoxicillin-clavulanic acid co-formulated dispersible
tablets at 28 ◦C and 23 ◦C; Table S5: Degradation of Amoxicillin in non-co-formulated suspensions
at 28 ◦C and 8 ◦C; Table S6: Degradation of Amoxicillin in non-co-formulated dispersible tablets at
28 ◦C and 23 ◦C; Table S7: Percentage (%) of households in represented African and Asian countries
having access to electricity or a refrigerator, assessed during DHS or MIS surveys from 2014–2018.
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